SPIOLTO® RESPIMAT® in COPD
SPIOLTO® RESPIMAT® in Chronic Obstructive Pulmonary Disease (COPD)
Comprehensive information on the efficacy, safety, mechanism of action and dosing & administration of SPIOLTO® RESPIMAT®.
Product information on the RESPIMAT® inhaler includes information about how RESPIMAT® is unique and how it delivers medication deep into the lungs with its unique mist.
Appropriate use of ICS in COPD
The GOLD 2017 Strategy Report recommends LAMA/LABA as the preferable first-line treatment* in symptomatic patients of GOLD groups B-D, regardless of exacerbation risk, and further restricts ICS-containing therapies in COPD.
Early loss of lung function in COPD
Optimising lung function from the start of maintenance therapy may help to keep patients engaged in their daily activities.
* In some patients initial therapy with LABA/ICS may be the first choice. These patients may have a history and/or findings suggestive of asthma-COPD overlap.